Analysts expect Nuvation Bio to report a Q2 2026 loss per share of $0.14 and revenue of $26.53 million, while the current $6.48 stock price suggests significant upside to the $11.00 analyst target. Investors are primarily focused on the commercial ramp-up of lead lung cancer drug IBTROZI and regulatory filing timelines for its broader oncology pipeline.
The company recently reported positive Phase 2 data for its brain cancer candidate safusidenib, reinforcing investor confidence in the mid-stage portfolio. Management is also expected to confirm that its $530 million cash position remains sufficient to fund operations through major clinical milestones in 2027.